Logo
x

Search

Subscribe Now

Bristol myers squibb

BMS Reports Data from the P-III (YELLOWSTONE) Study of Zeposia to Treat Moderate to Severe Active Crohn’s Disease

BMS Reports Data from the P-III (YELLOWSTONE) Study of Zeposia to Treat Moderate to Severe Active Crohn’s Disease

  • April 2, 2024
BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer

BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer

  • March 29, 2024
BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

  • December 8, 2023
BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan

BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan

  • December 7, 2023
Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation o...

  • May 17, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.